ARCALIS
Manufacturing · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Shimoota Kawauchisaku Minamisouma Shi Ha...Website
corp.arcalis.co.jpRevenue
$7.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About ARCALIS
株式会社ARCALIS is a pioneering CDMO in Japan specializing in mRNA, established in 2021 as a joint venture between Accelread and Arcturus Therapeutics. The company provides drug discovery support and CMC development services to pharmaceutical companies and biotech ventures, leveraging Arcturus's expertise in mRNA drug and vaccine research and manufacturing. ARCALIS is set to launch the world's first approved next-generation mRNA vaccine replicon in 2024, with a cGMP-compliant manufacturing facility in Fukushima. Their fully integrated development services include tailored mRNA design, LNP formulation, and comprehensive manufacturing capabilities.Explore more
Popular SearchesARCALIS IncSIC Code 28,283NAICS Code 32,325Show moreARCALIS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ARCALIS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ARCALIS
Check out if ARCALIS is spiking on competitors!
Click to see if ARCALIS had a recent Job posting/layoffs
Earning: See what the market has to say on ARCALIS recently announced quarterly report
Funding: Get notified immidiatlly once ARCALIS has new funding data
Check if ARCALIS has recently received funding, and reach out quickly before it becomes old news!
ARCALIS, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ARCALIS launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
ARCALIS is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ARCALIS is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ARCALIS.
ARCALIS Tech Stack
A closer look at the technologies used by ARCALIS
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Event
Product Marketing, Events, Sales, Search, Laboratory Operations, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Funding
Funding
Funding
ARCALIS News & Media
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS"). ARCALIS is a joint venture between Axcelead, Inc., which manages a group of world-class pharmaceutical and heal
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ARCALIS
Sign Up For FreeTo access detailed company insights
株式会社ARCALIS is a pioneering CDMO in Japan specializing in mRNA, established in 2021 as a joint venture between Accelread and Arcturus Therapeutics. The company provides drug discovery support and CMC development services to pharmaceutical companies and biotech ventures, leveraging Arcturus's expertise in mRNA drug and vaccine research and manufactu... Read More
